The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial - Université Paris-Est-Créteil-Val-de-Marne Accéder directement au contenu
Article Dans Une Revue European Heart Journal Année : 2021

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

John Cleland
João Pedro Ferreira
  • Fonction : Auteur
Beatrice Mariottoni
  • Fonction : Auteur
Pierpaolo Pellicori
Joe Cuthbert
Job Verdonschot
  • Fonction : Auteur
Johannes Petutschnigg
Fozia Ahmed
Franco Cosmi
  • Fonction : Auteur
Hans-Peter Brunner La Rocca
Mamas Mamas
  • Fonction : Auteur
Andrew Clark
  • Fonction : Auteur
Frank Edelmann
  • Fonction : Auteur
Burkert Pieske
  • Fonction : Auteur
Javed Khan
Ken Mcdonald
  • Fonction : Auteur
Philippe Rouet
Jan Staessen
  • Fonction : Auteur
Blerim Mujaj
Arantxa González
  • Fonction : Auteur
Javier Diez
  • Fonction : Auteur
Mark Hazebroek
Stephane Heymans
  • Fonction : Auteur
Roberto Latini
  • Fonction : Auteur
Stéphanie Grojean
Nicolas Girerd
  • Fonction : Auteur
Patrick Rossignol
  • Fonction : Auteur
Tim Collier
Faiez Zannad
Dan Atar
  • Fonction : Auteur
Lars Kober
  • Fonction : Auteur
Kenneth Dickstein
  • Fonction : Auteur
Theis Lange
  • Fonction : Auteur

Résumé

Abstract Aims To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. Methods and results Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or control for up to 9 months in people with, or at high risk of, coronary disease and raised plasma B-type natriuretic peptides. The primary endpoint was the interaction between baseline serum galectin-3 and changes in serum procollagen type-III N-terminal pro-peptide (PIIINP) in participants assigned to spironolactone or control. Procollagen type-I C-terminal pro-peptide (PICP) and collagen type-1 C-terminal telopeptide (CITP), reflecting synthesis and degradation of type-I collagen, were also measured. In 527 participants (median age 73 years, 26% women), changes in PIIINP were similar for spironolactone and control [mean difference (mdiff): −0.15; 95% confidence interval (CI) −0.44 to 0.15 μg/L; P = 0.32] but those receiving spironolactone had greater reductions in PICP (mdiff: −8.1; 95% CI −11.9 to −4.3 μg/L; P < 0.0001) and PICP/CITP ratio (mdiff: −2.9; 95% CI −4.3 to −1.5; <0.0001). No interactions with serum galectin were observed. Systolic blood pressure (mdiff: −10; 95% CI −13 to −7 mmHg; P < 0.0001), left atrial volume (mdiff: −1; 95% CI −2 to 0 mL/m2; P = 0.010), and NT-proBNP (mdiff: −57; 95% CI −81 to −33 ng/L; P < 0.0001) were reduced in those assigned spironolactone. Conclusions Galectin-3 did not identify greater reductions in serum concentrations of collagen biomarkers in response to spironolactone. However, spironolactone may influence type-I collagen metabolism. Whether spironolactone can delay or prevent progression to symptomatic heart failure should be investigated.

Dates et versions

hal-04391514 , version 1 (12-01-2024)

Identifiants

Citer

John Cleland, João Pedro Ferreira, Beatrice Mariottoni, Pierpaolo Pellicori, Joe Cuthbert, et al.. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42 (6), pp.684-696. ⟨10.1093/eurheartj/ehaa758⟩. ⟨hal-04391514⟩

Collections

IMRB UPEC
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More